Medtech Insight is part of the Informa Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

LivaNova PLC

www.livanova.com

Latest From LivaNova PLC

Market Brief: PBV Systems Fastest-Growing Segment In Global Surgical Heart Valve Management Market

The worldwide market for surgical heart valve products is expected to stay relatively flat, reaching $2bn in sales by 2023. The heart valve repair and replacement segments are expected to see small losses while the much smaller PBV systems market will grow at a CAGR of 12.7% by 2023, benefiting from a trend toward minimally invasive procedures.

Innovation Market Intelligence

Vagus Nerve Stimulation Ear Clip Reduces Atrial Fibrillation In Sham-Controlled Trial

Results of the TREAT AF trial showed low-level transcutaneous electrical stimulation of the auricular branch of the vagus nerve through the tragus of the patient’s ear reduced atrial fibrillation burden over six months.

Clinical Trials Innovation

LivaNova Launches RECOVER Trial Of VNS For Depression To Meet CMS CED Requirement

LivaNova's RECOVER trial will randomize about 1,000 patients with treatment-resistant depression to either LivaNova’s vagus nerve stimulation therapy or a sham therapy and follow them for at least a year.

Research & Development Starts & Stops

Vagus Nerve Stim Gets New Chance To Prove Its Worth For Depression

The US Centers for Medicare and Medicaid Services loosened its long-running noncoverage policy for vagus nerve stimulation for treatment-resistant depression a little bit, with a tightly controlled coverage-with-evidence-development policy. Device-maker LivaNova hopes to launch a Medicare-covered study later this year.

Market Access Reimbursement
See All

Company Information

  • Industry
  • Medical Devices
    • Implantable Devices
  • Therapeutic Areas
  • Cardiovascular
  • Neurology, Nervous System
  • Respiratory, Pulmonary
  • Alias(es)
  • Cyberonics Inc.
  • Ownership
  • Public
  • Headquarters
  • Worldwide
    • Europe
      • Western Europe
        • UK
  • Parent & Subsidiaries
  • LivaNova PLC
  • Senior Management
  • Damien McDonald, CEO
    Thad Huston, CFO
    Matthew J Dodds, SVP, Corp. Dev.
  • Contact Info
  • LivaNova PLC
    Phone: 203 786 5275
    20 Eastbourne Terr.
    London, TX W2 6LG
    UK
Advertisement
Advertisement
UsernamePublicRestriction

Register